Idexx Labs (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $384.19 to a high of $395.74. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $385.22...
, /PRNewswire/ --
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Is (IDXX) Outperforming Other Medical Stocks This Year?
Idexx (IDXX) delivered earnings and revenue surprises of 43.33% and 9.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.
Amid the pandemic situation, GW Pharmaceuticals (GWPH), which controls its own manufacture and supply chain, is expected to have faced minimum supply-related disruption unlike others.
Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CVS Health's (CVS) consumer centric digital strategy becomes even more relevant in Q2 with people increasingly using technology while staying at home.
STAAR Surgical's (STAA) ICL line of products is likely to have boosted Q2 performance amid the coronavirus pandemic.
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.
Henry Schein's (HSIC) medical business' PPE sales are likely to have boosted Q2 performance amid the coronavirus pandemic.
IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.
SmarTrend identified an Uptrend for Idexx Labs (NASDAQ:IDXX) on March 25th, 2020 at $212.26. In approximately 4 months, Idexx Labs has returned 69.45% as of today's recent price of $359.67.
With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.